As previously announced, a leading center in the
Massive bleeding is one of the leading causes of death in severe trauma. Evidence is growing suggesting that transfusion of whole blood is most appropriate in these cases, but the availability of blood group 0 whole blood with low levels (titers) of anti-A/B antibodies is limited. Thus, products/methods for the manufacturing of low titer-blood group 0 whole blood for use in massive transfusion may prove to be of significant clinical value in both civilian and military contexts.
The company's UBP product has been tested for this very purpose, to remove anti-A/B antibodies from blood group 0 whole blood, and the results will be presented as poster presentations around
The ambition of the company's pre-launch of the UBP product is, as previously announced, to allow well-selected leading centers to evaluate the product. Published results will create a platform for a wider launch.
The information was submitted for publication, through the agency of the contact person, on
Contact
E-mail: info@glycorex.se, phone: 046-286 52 30
Brief information about the company
Glycosorb® ABO is one of
The company has also developed a CE-marked medical device for the development of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases, as well as products for specific reduction of galectins. The company also develops products for the simultaneous reduction of blood group A/B specific antibodies and HLA antibodies (tissue-specific antibodies). The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the EU who have this disease.
https://news.cision.com/glycorex-transplantation/r/glycorex-transplantation-ab--gtab-b--universal-whole-blood--presentation-of-results-at-two-u-s--bloo,c3386750
https://mb.cision.com/Main/15286/3386750/1446267.pdf
(c) 2021 Cision. All rights reserved., source